Feasibility Study of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Intensity Modulated Radiotherapy in Resectable and Borderline Resectable Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 19 Apr 2017 Planned number of patients changed from 25 to 40.
- 22 Feb 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 27 Dec 2014 New trial record